BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15795351)

  • 1. The likelihood that PSA detection of early prostate cancers is associated with high mortality.
    Louria DB
    Arch Intern Med; 2005 Mar; 165(6):702. PubMed ID: 15795351
    [No Abstract]   [Full Text] [Related]  

  • 2. Prostate specific antigen: a useful screening test?
    Concato J
    Cancer J; 2000 Apr; 6 Suppl 2():S188-92. PubMed ID: 10803835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes?
    Carroll PR; Whitson JM; Cooperberg MR
    J Clin Oncol; 2011 Feb; 29(4):345-7. PubMed ID: 21189396
    [No Abstract]   [Full Text] [Related]  

  • 4. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
    Connolly D; Black A; Gavin A; Keane PF; Murray LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen and prostate cancer prognosis.
    Church TR
    J Natl Cancer Inst; 2006 Nov; 98(21):1509-10. PubMed ID: 17077347
    [No Abstract]   [Full Text] [Related]  

  • 8. Can we accurately identify men with low risk prostate cancer?
    Neal DE
    J Urol; 2008 Oct; 180(4):1217-8. PubMed ID: 18707718
    [No Abstract]   [Full Text] [Related]  

  • 9. Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer.
    Loeb S; Carter HB
    Urol Oncol; 2009; 27(6):583-4. PubMed ID: 19879470
    [No Abstract]   [Full Text] [Related]  

  • 10. Prostate-specific antigen dynamics and prostate cancer diagnosis.
    Bartoletti R
    Eur Urol; 2009 Nov; 56(5):761-2; discussion 763. PubMed ID: 19665286
    [No Abstract]   [Full Text] [Related]  

  • 11. Is prostate-specific antigen velocity useful in early detection of prostate cancer? A critical appraisal of the evidence.
    Etzioni RD; Ankerst DP; Weiss NS; Inoue LY; Thompson IM
    J Natl Cancer Inst; 2007 Oct; 99(20):1510-5. PubMed ID: 17925534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
    Höltl W; Lunglmayr G
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
    [No Abstract]   [Full Text] [Related]  

  • 13. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
    Ito K
    Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
    [No Abstract]   [Full Text] [Related]  

  • 14. Is an improved PSA screening test in sight?
    Savage L
    J Natl Cancer Inst; 2007 Oct; 99(20):1503-4. PubMed ID: 17925529
    [No Abstract]   [Full Text] [Related]  

  • 15. Survival benefit confirmed for prostate cancers diagnosed by PSA testing.
    Lamb DS; Delahunt B; Denham J; Slaney D
    N Z Med J; 2009 Jul; 122(1299):67-70. PubMed ID: 19684649
    [No Abstract]   [Full Text] [Related]  

  • 16. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.
    Perrin P
    Eur Urol; 2006 Mar; 49(3):418-9. PubMed ID: 16459016
    [No Abstract]   [Full Text] [Related]  

  • 17. [PSA level--is 4.0 ng/ml as upper limit too high].
    Aktuelle Urol; 2005 Jun; 36(3):181-8. PubMed ID: 16001334
    [No Abstract]   [Full Text] [Related]  

  • 18. Validity and legacy of prostate-specific antigen (PSA) and PSA-based parameters and isoforms in the new millennium.
    Djavan B
    Eur Urol; 2010 Jun; 57(6):928-9. PubMed ID: 20304552
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostate cancer risk assessment program: a 10-year update of cancer detection.
    Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D
    J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Early detection of cancer of the prostate. Pros and cons].
    Hoesl CE; Altwein JE
    MMW Fortschr Med; 2005 Apr; 147(14):32, 34-6. PubMed ID: 15887681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.